Print

P2G12 (FuturePharma)

Phase I Dose Escalation Placebo Controlled Trial to Evaluate Safety and Reactogenicity of Single IV Administration of P2G12

Trial Details:

I Ongoing
St George's, University of London March 02, 2017
P2G12 human monoclonal antibody
P2G12 Passive Immunization
United Kingdom 23
NCT02923999
https://www.clinicaltrials.gov/ct2/show/NCT02923999